Brand name
Neoprofen, the original
We didn’t find a savings card or cash price from Neoprofen’s maker. Ask the pharmacy for Neoprofen’s cash price. With insurance, ask what your plan charges.
Generic name: ibuprofen lysine
Used for: Closing an open heart vessel (PDA) in premature babies
Given by your care team
Billed by the clinic
Neoprofen is given by a doctor or nurse, not picked up at a pharmacy.
Your care team and your insurance decide which product you get.
Neoprofen, the original
We didn’t find a savings card or cash price from Neoprofen’s maker. Ask the pharmacy for Neoprofen’s cash price. With insurance, ask what your plan charges.
The same medicine as Neoprofen, without the brand name
The same medicine as Neoprofen, without the brand name. Its NDC is the number that names the exact product: give it to the pharmacy and they can look it up or order it.
ibuprofen lysine
Given by your care team
This is given in the hospital to premature babies, not picked up at a pharmacy.
NDC (for your care team)
What to ask your care team
“Which version of Neoprofen do you use: the brand, the authorized generic or a regular generic? What would I pay for each?”
Source: FDA, updated November 16, 2026
Official labels and ingredient lists from DailyMed (U.S. National Library of Medicine).
Same active and inactive ingredients as Neoprofen.
Active: ibuprofen lysine 10 mg/mL
Inactive, on both labels:
Same active ingredient as Neoprofen. Fillers and dyes can differ.
One company sells an FDA-rated generic of Neoprofen. It’s given by your care team, who choose which one to use.
Product page on xgenpharmadjb.com
10 mg/mL
| Package | NDC |
|---|---|
| Carton of 6 mL | 39822-1030-2 |
Inactive ingredients: water
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
NeoProfen is a nonsteroidal anti-inflammatory drug indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA.
Source: the FDA label for Neoprofen (Recordati Rare Diseases Inc.), October 15, 2024. Full label on DailyMed
Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/neoprofen/